Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Deferred Taxes (2021 - 2024)

Historic Deferred Taxes for Prime Medicine (PRME) over the last 4 years, with Q2 2024 value amounting to -$134000.0.

  • Prime Medicine's Deferred Taxes fell 53225.81% to -$134000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was -$134000.0, marking a year-over-year decrease of 33508.77%. This contributed to the annual value of -$279000.0 for FY2023, which is 7105.81% up from last year.
  • Latest data reveals that Prime Medicine reported Deferred Taxes of -$134000.0 as of Q2 2024, which was down 53225.81% from $134000.0 recorded in Q1 2024.
  • Prime Medicine's 5-year Deferred Taxes high stood at $1.2 million for Q4 2021, and its period low was -$532000.0 during Q1 2022.
  • Its 4-year average for Deferred Taxes is $0.0, with a median of -$121000.0 in 2023.
  • The largest annual percentage gain for Prime Medicine's Deferred Taxes in the last 5 years was 16633.66% (2024), contrasted with its biggest fall of 53225.81% (2024).
  • Over the past 4 years, Prime Medicine's Deferred Taxes (Quarter) stood at $1.2 million in 2021, then plummeted by 116.25% to -$202000.0 in 2022, then soared by 46.53% to -$108000.0 in 2023, then decreased by 24.07% to -$134000.0 in 2024.
  • Its Deferred Taxes stands at -$134000.0 for Q2 2024, versus $134000.0 for Q1 2024 and -$108000.0 for Q3 2023.